Medtronic Stengthens Hand in Ablation Market with CryoCath Acquisition

Article preview reprinted from IN VIVO - October 2008

Find out how competitors in the cardiac rhythm management space are drawing new battlelines in the area of atrial ablation. Medtronic's acquisition of CryoCath pits it against historical rivals St. Jude and Boston Scientific.

Medtronic Stengthens Hand in Ablation Market with CryoCath Acquisition

Article preview reprinted from IN VIVO - October 2008

The cardiac ablation market—particularly for atrial fibrillation—is shaping into a potential battleground between the same factions who once dominated and then suffered through the troubled cardiac rhythm management (CRM) space. This time, Medtronic Inc. anted up with its $400 million bid to acquire CryoCath Technologies Inc., a company developing a cryoablation method to treat common, yet debilitating, cardiac arrhythmias. (See "AF Ablation: The Pulse of Innovation," Medtech Insight, September 2008

The acquisition, if approved, tightens Medtronic's competition with other CRM companies including Boston Scientific Corp., which augmented its own cardiac ablation offerings with the acquisition of CryoCor Inc., a CryoCath rival, earlier this year. Meanwhile, St. Jude Medical Inc. stepped up with its own acquisition of EP MedSystems Inc., a supplier of an intra-cardiac system for the diagnosis and monitoring of arrhythmias, for $91 million.

Purchase this 1030-word article online as a PDF for just $85 and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed. Subscribe to IN VIVO.

Companies mentioned in this article:

AtriCure Inc.
Boston Scientific Corp.
CryoCor Inc.
CR Bard Inc.
CryoCath Technologies Inc.
EP MedSystems Inc.
Johnson & Johnson
Biosense Webster Inc.
Medtronic Inc.
St. Jude Medical Inc.

IN VIVO delivers:

• Revealing, in-depth coverage of your competitors' strategies
• Incisive projections of future industry trends and their implications for your business
• Expert analysis of key industry developments
• Exclusive interviews with top industry executives and analysts
• In-depth examination of dealmaking, marketing, R&D, regulatory, and finance strategies -- those that were successful and those that missed the mark
• Subscribe to IN VIVO today!